Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) closed the day trading at $22.54 up 0.94% from the previous closing price of $22.33. In other words, the price has increased by $0.94 from its previous closing price. On the day, 0.99 million shares were traded. CNTA stock price reached its highest trading level at $22.9763 during the session, while it also had its lowest trading level at $22.13.
Ratios:
For a better understanding of CNTA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.57 and its Current Ratio is at 10.57. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.39.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Stephens on October 28, 2025, initiated with a Overweight rating and assigned the stock a target price of $35.
On September 03, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $31.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 27 ’25 when Accardi Mario Alberto sold 8,000 shares for $25.00 per share. The transaction valued at 200,000 led to the insider holds 194,394 shares of the business.
Accardi Mario Alberto bought 8,000 shares of CNTA for $200,000 on Oct 27 ’25. On Oct 15 ’25, another insider, HUSSAIN IQBAL J, who serves as the General Counsel of the company, sold 6,000 shares for $22.41 each. As a result, the insider received 134,439 and left with 105,386 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 3030454528 and an Enterprise Value of 2784822016. For the stock, the TTM Price-to-Sale (P/S) ratio is 201.18 while its Price-to-Book (P/B) ratio in mrq is 10.05. Its current Enterprise Value per Revenue stands at 185.655 whereas that against EBITDA is -13.054.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.58, which has changed by 0.23506641 over the last 52 weeks, in comparison to a change of 0.14151978 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $25.42, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is 0.12%, while the 200-Day Moving Average is calculated to be 34.87%.
Shares Statistics:
Over the past 3-months, CNTA traded about 1.30M shares per day on average, while over the past 10 days, CNTA traded about 2024710 shares per day. A total of 134.42M shares are outstanding, with a floating share count of 85.46M. Insiders hold about 36.42% of the company’s shares, while institutions hold 57.02% stake in the company. Shares short for CNTA as of 1761868800 were 5153546 with a Short Ratio of 4.01, compared to 1759190400 on 4991915. Therefore, it implies a Short% of Shares Outstanding of 5153546 and a Short% of Float of 4.5100003.
Earnings Estimates
Centessa Pharmaceuticals plc ADR (CNTA) is presently subject to a detailed evaluation by 8.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.37 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$1.33 and -$1.42 for the fiscal current year, implying an average EPS of -$1.38. EPS for the following year is -$1.68, with 10.0 analysts recommending between -$1.37 and -$2.02.
